# Accepted Manuscript

Title: Prevention of CMV Reactivation in Haploidentical Stem Cell Transplantation

Author: Aimee E. Hammerstrom, Lindsey R. Lombardi, Sai Ravi Pingali, Gabriela Rondon, Julianne Chen, Denái R. Milton, Roy F. Chemaly, Richard E. Champlin, Alison Gulbis, Stefan O. Ciurea


PII: S1083-8791(17)30751-6

DOI: https://doi.org/doi:10.1016/j.bbmt.2017.09.018

Reference: YBBMT 54810

To appear in: Biology of Blood and Marrow Transplantation

Received date: 12-6-2017 Accepted date: 28-9-2017



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## ACCEPTED MANUSCRIPT

## Prevention of CMV reactivation in Haploidentical Stem Cell Transplantation

Aimee E. Hammerstrom, PharmD<sup>1</sup>, Lindsey R. Lombardi, PharmD<sup>1</sup>, Sai Ravi Pingali, MD<sup>2</sup>, Gabriela Rondon, MD<sup>2</sup>, Julianne Chen, BS<sup>2</sup>, Denái R. Milton, MS<sup>3</sup>, Roy F. Chemaly, MD<sup>4</sup>, Richard E. Champlin, MD<sup>2</sup>, Alison Gulbis, PharmD<sup>1</sup>, Stefan O. Ciurea, MD<sup>2</sup>

The University of Texas MD Anderson Cancer Center <sup>1</sup>Division of Pharmacy; <sup>2</sup>Department of Stem Cell Transplantation and Cellular Therapy; <sup>3</sup>Department of Biostatistics; <sup>4</sup>Department of Infectious Diseases, Infection Control, and Employee Health

Financial Disclosure Statement: No relevant conflict of interest to disclose.

Short title: Prevention of CMV reactivation in HaploSCT

#### **Corresponding Author:**

Name: Aimee Hammerstrom

Address: 1515 Holcombe Blvd Unit 377, Houston, TX 77030

Phone: 713-792-1060 Fax: 713-563-9952

Email Address: aehammer@mdanderson.org

#### Highlights:

- Prolonged time to CMV reactivation in haploidentical transplants was observed with ganciclovir administered before and valacyclovir administered after transplant
- A lower incidence of CMV reactivation and CMV disease was noted with this combined approach compared to traditional antiviral prophylaxis
- No higher toxicity or non-relapsed mortality was observed with combination therapy

#### **ABSTRACT**

Cytomegalovirus (CMV) infection can increase the morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Due to a higher degree of immunosuppression, haploidentical transplant recipients may be at an increased risk of viral infections, particularly CMV. We retrospectively analyzed 86 haploidentical HCT recipients at our institution, to determine whether a more intensified antiviral strategy would reduce the incidence of CMV reactivation compared with a traditional antiviral prophylaxis regimen. According to practice changes over time in antiviral prophylaxis

### Download English Version:

# https://daneshyari.com/en/article/8430349

Download Persian Version:

https://daneshyari.com/article/8430349

<u>Daneshyari.com</u>